CROHN'S DISEASE

This study tests a new drug called AZD7798 in 30 adults with active Crohn's disease who have an ileostomy. The goal is to see if the drug is safe and helps heal the lining of the small intestine compared to a placebo. Participants will be randomly assigned to receive either the d…

This study tests whether a newer surgical method (Kono-S) is better than the standard approach at preventing Crohn's disease from returning after bowel surgery. About 600 adults with Crohn's disease needing surgery will take part. The main goal is to see if the Kono-S technique l…

This study follows about 240 people in Japan with moderate to severe Crohn's disease who are prescribed upadacitinib. Researchers will monitor side effects and how well the drug controls the disease over up to 64 weeks. Participants receive the drug as part of their normal care, …

This study is testing whether the drug vorinostat is safe and can help control symptoms in people with moderate-to-severe Crohn's disease that hasn't responded to standard treatments. Participants who respond well may then receive maintenance therapy with another drug, ustekinuma…

This study looks at the long-term safety of a drug called vedolizumab in children and teenagers with ulcerative colitis or Crohn's disease. About 70 participants who responded well to the drug in an earlier study will continue treatment, while others will be monitored for up to 2…

This study tests several new investigational drugs in 140 adults with moderate-to-severe Crohn's disease or ulcerative colitis. The main goals are to check safety and see if the drugs can improve symptoms and reduce gut inflammation seen on camera exams. Participants must have a …

This study watches how well IL-23 inhibitors work for adults with active Crohn's disease in everyday medical practice. About 665 participants will get treatment chosen by their doctor and be checked at 12 and 52 weeks for symptom relief, healing, and side effects. The goal is to …

This study tests whether adding the antifungal drug fluconazole to standard IL-23 therapy helps people with Crohn's disease feel better. About 120 adults with mild to moderate Crohn's will either get fluconazole or a placebo alongside their usual treatment. The goal is to see if …

This program provides children and teenagers with moderate to severe ulcerative colitis or Crohn's disease continued access to vedolizumab, a medication given through an IV. It is for those who completed a prior study and still benefit from the treatment, with no suitable alterna…

This study looks at the long-term safety of the drug vedolizumab in children with ulcerative colitis or Crohn's disease. It is for kids who already completed a previous study on this drug. Researchers will track side effects and major health events like infections or surgeries ov…

This study tests an experimental drug called SAR442970 in adults with moderate to severe Crohn's disease. About 99 participants will receive either the drug or a placebo to see if it can reduce gut inflammation. The study lasts up to 168 weeks, with an option to continue the drug…

This study tests four different medicines (risankizumab, trosunilimab, lutikizumab, and ABBV-8736) in about 540 adults with moderate to severe Crohn's disease. The goal is to see if these targeted therapies can reduce inflammation and improve symptoms. Participants will receive i…

This study looks at the long-term safety of an oral medication called zasocitinib (TAK-279) for people with moderate to severe Crohn's disease or ulcerative colitis. Participants who responded well to the drug in earlier studies can continue treatment for up to 3 years. The main …

This study tests a drug called guselkumab in 120 children with moderate to severe Crohn's disease. The goal is to see if the drug can reduce symptoms and heal the gut lining after one year of treatment. Participants must have active Crohn's disease confirmed by endoscopy. The stu…

This study monitors 275 people in Japan receiving darvadstrocel, a special cell injection, for complex anal fistulas caused by Crohn's disease. Researchers will track side effects and whether fistulas close over 36 months. The goal is to see if this treatment safely improves symp…

This study tests whether combining two drugs (vedolizumab with adalimumab or ustekinumab) works better than one for adults with moderate to severe Crohn's disease. In the first part, 100 participants get the dual therapy for 26 weeks. Those who respond then switch to vedolizumab …

This study tests a new drug called MORF-057 in adults with moderate to severe Crohn's disease, a condition that causes inflammation in the gut. About 385 people will receive either one of three doses of the drug or a placebo to see if it helps heal the gut lining and reduce sympt…

This study tests a drug called mirikizumab in 90 children with moderate to severe Crohn's disease. The goal is to see if it can reduce symptoms and heal the gut lining over 52 weeks. Participants will receive the drug or another treatment, with regular checkups for about 74 weeks…

This study will follow 500 people with Crohn's disease or ulcerative colitis who are starting guselkumab, a biologic drug. Researchers want to see how well the drug controls symptoms like diarrhea and rectal bleeding, and how it affects fatigue, quality of life, and work producti…

This study looks at how well two approved drugs, upadacitinib and risankizumab, work as second-line treatments for people with moderate-to-severe Crohn's disease. About 250 participants in Italy will take the drugs as prescribed by their doctor and be followed for up to 18 months…

This study is tracking 220 adults in the UK with moderate to severe ulcerative colitis or Crohn's disease who are starting guselkumab, a biologic treatment. Researchers want to see how well the drug controls symptoms and helps patients achieve remission without needing steroids. …

This study tests whether adding a weight-loss drug (tirzepatide) to a standard Crohn's treatment (mirikizumab) helps people with both Crohn's disease and obesity or overweight. About 290 adults will receive either mirikizumab alone or mirikizumab plus tirzepatide for up to 61 wee…

This study tests a new drug, duvakitug, in about 980 adults with moderate to severe Crohn's disease who haven't responded well to other treatments. Participants will receive either duvakitug or a placebo for 12 weeks to see if it can reduce symptoms and heal the gut lining. The g…

This study looks at how well and how safely the drug mirikizumab works over a long period (about 3 years) in children and teenagers with moderate-to-severe ulcerative colitis or Crohn's disease. About 150 participants who have already been in earlier studies will continue treatme…

This study tests an experimental drug called SAR441566 in 260 adults with moderate to severe Crohn's disease. The goal is to see if the drug can reduce inflammation and damage in the intestines better than a placebo. Participants will receive either the drug or a placebo for up t…

This study tests a subcutaneous (under the skin) version of vedolizumab in 70 children with moderate to severe ulcerative colitis or Crohn's disease who already responded to the IV form. The goal is to see how the body handles the drug and if it is safe. Participants receive the …

This study tests a treatment for people with severe Crohn's disease that hasn't responded to other therapies. It uses high-dose chemotherapy followed by a transplant of the patient's own specially selected stem cells. The goal is to see if this approach can safely control the dis…

This study looks at whether a special liquid diet, called exclusive enteral nutrition (EEN), can help adults with active Crohn's disease feel better and reduce inflammation. About 300 participants will use EEN as their main treatment for 12 weeks. Researchers will track remission…

This study tests a new medicine called duvakitug for people with moderate to severe Crohn's disease who have already responded to treatment. The goal is to see if duvakitug can help keep the disease in remission longer than a placebo. About 751 adults will take part, and the stud…

This study tests an oral drug, upadacitinib, in children aged 2 to 18 with moderate-to-severe Crohn's disease who haven't improved with other treatments. The goal is to see if the drug can reduce inflammation and improve symptoms like belly pain and diarrhea. The trial involves a…

This study tests an oral medication called TAK-279 in people with moderate to severe Crohn's disease, a condition that causes gut inflammation. About 268 adults will receive either one of three doses of TAK-279 or a placebo for 12 weeks to see if it reduces bowel inflammation and…

This study looks at whether vedolizumab can help people with moderate to severe ulcerative colitis or Crohn's disease achieve remission (no symptoms) after 14 weeks of treatment. About 400 adults aged 18 to 80 will receive vedolizumab first as an IV infusion, then as a shot under…

This study is for people with Crohn's disease whose current medicine (adalimumab) is no longer working well. It compares two options: increasing the dose of adalimumab or switching to a different drug called vedolizumab. The goal is to see which approach better controls symptoms …

This study looks at whether adding a special diet called the Crohn's Disease Exclusion Diet (CDED) to regular medication can help children and teens with unstable Crohn's disease avoid flare-ups for a full year. About 120 participants aged 6-17 will be randomly assigned to either…

This study tests a new drug called tulisokibart in 1,200 people with moderate-to-severe Crohn's disease. The goal is to see if it can reduce symptoms and heal the gut better than a placebo. Participants must have tried other treatments without success. The study lasts up to 52 we…

This study tests a drug called vedolizumab for people in China with moderate to severe Crohn's disease, a condition that causes inflammation in the gut. About 408 adults will receive either the drug or a placebo to see if it reduces symptoms like belly pain and diarrhea. The goal…

This study tests a drug called risankizumab in children aged 2 to 18 with moderate to severe Crohn's disease. The goal is to see if it can reduce gut inflammation and improve symptoms like belly pain and diarrhea. Participants will receive the medicine through an IV or injection …

This study tests whether a special PET scan can find early scarring in the small bowel of people with Crohn's disease. About 45 adults with Crohn's will get the scan, and researchers will compare those with known strictures to those without. The goal is to see if the scan can det…

This study compares a quick, abbreviated MRI scan to the standard longer scan in 300 children and adults with Crohn's disease. The goal is to see if the shorter scan is just as good at finding inflammation, narrowing, or other problems in the bowel. Participants will also share w…

This study tests whether adding a coping skills program to standard biologic medication helps people with early Crohn's disease (diagnosed less than 5 years) feel better emotionally and physically. About 170 adults with active Crohn's will be randomly assigned to receive either t…

This pilot study from Mayo Clinic tests whether virtual reality (VR) can safely reduce abdominal pain in people with Crohn's disease who are not currently experiencing active inflammation. The study will enroll 15 participants who have ongoing pain despite normal inflammation mar…

This study aims to understand why Crohn's disease often comes back after surgery by examining specific immune cells that respond to a protein called IL-23. Researchers will collect tissue samples from 40 adults with Crohn's disease during routine endoscopies before and after 12-1…

This study is observing 600 adults in South Korea who are already receiving vedolizumab injections for ulcerative colitis or Crohn's disease. Researchers will look at medical records to track side effects and how well the treatment works. No new treatments are given—this is just …

This study watches 300 adults with Crohn's disease who are starting vedolizumab or an IL-23 blocker for the first time. Researchers will track how quickly patients feel improvements in pain, fatigue, mood, and daily activities using simple questionnaires. The goal is to learn whe…

This study collects health information from up to 10,000 people with conditions like Long COVID, ME/CFS, and autoimmune diseases. Participants use a phone app to share symptoms, wearables data, and lifestyle details. The goal is to help researchers better understand these illness…

This study looks at how pregnancy, childbirth, and breastfeeding affect inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Researchers will follow 945 women from a French registry to count disease flare-ups during and after pregnancy. The goal is …

This study looks at how doctors around the world use a 'treat-to-target' approach for people with Crohn's disease or ulcerative colitis. Researchers will review medical records from 2,000 adults over 24 months to see if adjusting treatment based on regular check-ups leads to bett…